Helicobacter Pylori Infections - Pipeline Insight, 2020
This report can be delivered to the clients within 24-48 Hours
DelveInsight’s, “Helicobacter Pylori Infections – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Helicobacter Pylori Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Helicobacter Pylori Infections: Overview
Helicobacter pylori (H. pylori) is a gram-negative, microaerophilic, spiral-shaped and flagellated bacterium infecting about half the world’s population whose main reservoir is the human stomach. H. pylori possesses microbiological characteristics that allow it to survive in extremely adverse conditions such as the gastric acidic environment. H. pylori infection is the main cause of chronic gastritis and peptic ulcer disease. H. pylori has a determinant pathogenic role in the development of distal gastric adenocarcinoma and gastric mucosa associated lymphoid tissue (MALT) lymphoma; in fact, it can contribute to gastric carcinogenesis by stimulating gastric cell proliferation without counterbalancing with adequate apoptosis.
Symptoms
The symptoms of Helicobacter Pylori Infections include:
H. pylori infection can be diagnosed by noninvasive methods or by endoscopic biopsy of the gastric mucosa; the selection of the appropriate test depends on the clinical setting. Noninvasive methods include the urea breath test, serologic tests, and stool antigen assays. The urea breath test relies on the abundant, H. pylori–derived urease activity in the stomach; it qualitatively detects active infection with a sensitivity and specificity of more than 90 percent. The test is indicated for the initial diagnosis of the infection and for follow-up of eradication therapy.
Treatment
Antibiotics are combined with proton-pump inhibitors or ranitidine bismuth citrate and so-called triple therapies, combinations of one antisecretory agent with two antimicrobial agents for 7 to 14 days, have been extensively evaluated, and several regimens have been approved by the Food and Drug Administration (FDA). The combination of two or more antimicrobial agents increases rates of cure and reduces the risk of selecting for resistant H. pylori. The chief antimicrobial agents used in these regimens are amoxicillin, clarithromycin, metronidazole, tetracycline, and bismuth.
Gastroparesis Emerging Drugs
Further product details are provided in the report……..
Helicobacter Pylori Infections: Therapeutic Assessment
This segment of the report provides insights about the different Helicobacter Pylori Infections drugs segregated based on following parameters that define the scope of the report, such as:
Helicobacter Pylori Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Helicobacter Pylori Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Helicobacter Pylori Infections drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Helicobacter Pylori Infections – Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Helicobacter Pylori Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Helicobacter Pylori Infections: Overview
Helicobacter pylori (H. pylori) is a gram-negative, microaerophilic, spiral-shaped and flagellated bacterium infecting about half the world’s population whose main reservoir is the human stomach. H. pylori possesses microbiological characteristics that allow it to survive in extremely adverse conditions such as the gastric acidic environment. H. pylori infection is the main cause of chronic gastritis and peptic ulcer disease. H. pylori has a determinant pathogenic role in the development of distal gastric adenocarcinoma and gastric mucosa associated lymphoid tissue (MALT) lymphoma; in fact, it can contribute to gastric carcinogenesis by stimulating gastric cell proliferation without counterbalancing with adequate apoptosis.
Symptoms
The symptoms of Helicobacter Pylori Infections include:
- Anemia
- Gastrointestinal bleeding
- Weight loss
- Frequent burping
- Bloating
H. pylori infection can be diagnosed by noninvasive methods or by endoscopic biopsy of the gastric mucosa; the selection of the appropriate test depends on the clinical setting. Noninvasive methods include the urea breath test, serologic tests, and stool antigen assays. The urea breath test relies on the abundant, H. pylori–derived urease activity in the stomach; it qualitatively detects active infection with a sensitivity and specificity of more than 90 percent. The test is indicated for the initial diagnosis of the infection and for follow-up of eradication therapy.
Treatment
Antibiotics are combined with proton-pump inhibitors or ranitidine bismuth citrate and so-called triple therapies, combinations of one antisecretory agent with two antimicrobial agents for 7 to 14 days, have been extensively evaluated, and several regimens have been approved by the Food and Drug Administration (FDA). The combination of two or more antimicrobial agents increases rates of cure and reduces the risk of selecting for resistant H. pylori. The chief antimicrobial agents used in these regimens are amoxicillin, clarithromycin, metronidazole, tetracycline, and bismuth.
Gastroparesis Emerging Drugs
- TAK-438: Takeda
- Tegoprazan: Pfizer
Further product details are provided in the report……..
Helicobacter Pylori Infections: Therapeutic Assessment
This segment of the report provides insights about the different Helicobacter Pylori Infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Helicobacter Pylori Infections There are approx. 10+ key companies which are developing the therapies for Helicobacter Pylori Infections. The companies which have their Helicobacter Pylori Infections drug candidates in the most advanced stage, i.e. phase III include, Takeda.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Helicobacter Pylori Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Helicobacter Pylori Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Helicobacter Pylori Infections drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Helicobacter Pylori Infections R&D. The therapies under development are focused on novel approaches to treat/improve Helicobacter Pylori Infections.
- In April 2020, Meridian Bioscience, Inc. a provider of diagnostic testing solutions and life science raw materials, has completed its previously announced acquisition of Exalenz Bioscience Ltd., the Modiin, Israel based provider of the BreathID Breath Test Systems, a urea breath test platform for the detection of Helicobacter pylori.
- Helicobacter Pylori Infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Helicobacter Pylori Infections drugs?
- How many Helicobacter Pylori Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Helicobacter Pylori Infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Helicobacter Pylori Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Helicobacter Pylori Infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- Takeda
- Pfizer
- Servatus Biopharmaceuticals
- TAK-408
- Tegoprazan
- SVT-1C469
Introduction
Executive Summary
Helicobacter Pylori Infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Helicobacter Pylori Infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Helicobacter Pylori Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Helicobacter Pylori Infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
TAK-438: Takeda
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Metopimazine: Neurogastrx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
SVT-1C469: Servatus Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
RQ 00201894: RaQualia Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Helicobacter Pylori Infections Key Companies
Helicobacter Pylori Infections Key Products
Helicobacter Pylori Infections - Unmet Needs
Helicobacter Pylori Infections - Market Drivers and Barriers
Helicobacter Pylori Infections - Future Perspectives and Conclusion
Helicobacter Pylori Infections Analyst Views
Helicobacter Pylori Infections Key Companies
Appendix
Executive Summary
Helicobacter Pylori Infections: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Helicobacter Pylori Infections – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Helicobacter Pylori Infections companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Helicobacter Pylori Infections Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
TAK-438: Takeda
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
Metopimazine: Neurogastrx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
SVT-1C469: Servatus Biopharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
RQ 00201894: RaQualia Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Helicobacter Pylori Infections Key Companies
Helicobacter Pylori Infections Key Products
Helicobacter Pylori Infections - Unmet Needs
Helicobacter Pylori Infections - Market Drivers and Barriers
Helicobacter Pylori Infections - Future Perspectives and Conclusion
Helicobacter Pylori Infections Analyst Views
Helicobacter Pylori Infections Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Helicobacter Pylori Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Helicobacter Pylori Infections
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Helicobacter Pylori Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Helicobacter Pylori Infections
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
